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Introduction
Hepatitis B infection is a common cause of chronic liver 
disease. The World Health Organization (WHO) estimates 
that 257 million people are living with hepatitis B (1). 
In 2015, over 800,000 deaths worldwide were attributed 
to complications of hepatitis B infection; the majority of 
which were related to complications of chronic infection 
such as the development of cirrhosis and hepatocellular 
carcinoma (HCC) (1). The significant morbidity and 
mortality associated with chronic hepatitis B (CHB) has led 
to a flurry of research and advances in understanding the 
pathophysiology and natural history of the infection. This 
knowledge has led to development of novel therapies for 
treatment. This article is aimed at reviewing characteristics 
of HBV, its impact on development of HCC, the criteria 
for treatment of CHB, and current first-line and future 
therapies.
HBV characteristics
The hepatitis B virus (HBV) is composed of a partially 
double-stranded DNA genome packaged with an 
HBV polymerase (2). The genome is covered by a 
protein capsid, the so-called hepatitis B core antigen 
(HBcAg), which is then enclosed in a lipid bilayer that 
contains surface proteins, the hepatitis B surface antigen 
(HBsAg) (2). The HBsAg assists the virus particle in 
gaining entry into hepatocytes (2). Once the virus infects 
a hepatocyte, the partially double-stranded DNA is 
transformed into a stable circular form called covalently 
closed circular DNA (cccDNA) (3). The cccDNA is very 
stable and a difficult to eradicate form of the HBV genome 
that resides in the hepatocyte for the life of the cell (3). 
Replication of the virus consists of transcription of the 
cccDNA into pre-genomic RNA that is reverse transcribed 
to HBV DNA before being packaged into another viral 
particle (4). 
Several key areas of the HBV genome with clinical 
relevance beyond viral assembly are the core and precore 
regions. These regions are involved in assembly of the 
HBcAg and the Hepatitis B e-antigen (HBeAg) (3). The 
precore region is transcribed into precore mRNA that is 
translated into a single peptide, which is than cleaved to 
form HBeAg (2). The function of HBeAg is still not well 
defined but mutations involving the precore region are 
associated with the development of HBeAg-negative chronic 
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hepatitis B (5,6). There is also an increased likelihood of 
seroconversion of HBeAg or going from HBeAg positive 
to HBeAg negative with anti-HBe (5,6). Despite increased 
rates of seroconversion and lower levels of viremia, 
HBeAg-negative hepatitis B with precore mutations is 
associated with older individuals and more advanced liver 
disease (7). The core region is also associated with advanced 
liver disease, as well as an increased risk of HCC, but 
mutations in the core region are not as firmly correlated with 
HBeAg-negative HBV as precore mutations (8,9). Identifying 
variants of the core and precore regions is not standard 
practice when evaluating which patients require treatment; 
however, it can be useful in stratifying patients who are at 
highest risk of progression of CHB to cirrhosis (10).
In addition to the mutations in the core/precore regions 
of the HBV genome, there are many different genotypes 
of HBV, and several subtypes within each genotype (11). 
These genotypes are lettered from A to J and generally 
have a unique geographical distribution (11). Similar to the 
precore/core mutations, the clinical utility of identifying 
the HBV genotype can provide further information on 
the risk of disease progression and development of HCC 
(10,11). For example, genotype B has been associated with a 
milder form of chronic hepatitis B with slower progression 
of disease and a higher likelihood of HBeAg seroconversion 
when compared with genotype C (12). Genotype testing 
is not yet standard of care but can help guide treatment 
considerations and monitoring for CHB. 
Diagnosis of HBV infection
Serological markers are the primary method by which 
infection with HBV is diagnosed. The presence of HBsAg 
is diagnostic of infection and if present for more than 
6 months is indicative of chronic infection. Multiple phases 
of CHB have been identified, each with its own treatment 
implications (10,13,14). These are listed in Table 1. 
Screening for HBV is recommended in areas where 
prevalence is considered high (>2% prevalence) (4). The 
risk of developing CHB varies by age with infants less than 
1 year of age having a >80% chance of developing CHB 
whereas toddlers between 1 and 6 years have between a 
30–50% risk (1). Less than 5% of adults with an acute 
infection will develop CHB but close to a third of these 
patients who acquire CHB will develop advanced liver 
disease and/or HCC (1). 
Risk factors for progression of HBV chronic liver 
disease
Several risk factors for progression of CHB to cirrhosis 
have been identified. HBV DNA level in blood, specifically 
a level >104 copies/mL, was one of the strongest predictors 
of progression to cirrhosis (15). This was independent of 
ALT, HBeAg status, age, and other factors (15). Older age is 
also a strong predictor of progression, but this is more likely 
due longer duration of disease rather than an independent 
risk factor (16). Another commonly associated risk factor 
is male sex although the exact mechanism is not well 
understood (16). 
The overall incidence of cirrhosis in patients with HBeAg-
positive hepatitis B was 1.6 and 3.8 per 100 person-years 
in East Asian and European countries, respectively (16). In 
patients with HBeAg-negative chronic hepatitis B the 
incidence was 2.8 and 9.7 for the same East Asian and 
European countries, respectively (16). The incidence in 
per 100 person-years roughly corresponds to a 5-year 
cumulative incidence of 8% and 17% in the HBeAg-
positive CHB compared to a 5-year incidence of 13% and 
38% in HBeAg-negative CHB in East Asian and European 
countries, respectively (16). While this seems to indicate 
that HBeAg-negative CHB is a risk factor for progression to 
Table 1 CHB serologic interpretation
Variables HBsAg HBeAg HBV DNA Anti-HBe
Inactive CHB** + – – +
HBeAg-positive CHB* + + +/++ –
HBeAg-negative CHB* + – +/++ +
Immune-tolerant CHB** + + +++ –
Immune-active CHB*** + +/– ++/+++ +/–
*, serum ALT levels can fluctuate from normal to abnormal; **, serum ALT levels are normal in these cases; ***, serum ALT levels are 
elevated. 
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cirrhosis, this is also likely related to duration of disease (16). 
Other risk factors associated with increased progression to 
cirrhosis include HBV genotype, presence of co-infections of 
hepatitis C or hepatitis D, and presence of other chronic liver 
diseases such as non-alcohol steatohepatitis (NASH) (16).
Liver cancer and HBV
HBV is the most common cause of HCC, being responsible 
for >50% of cases worldwide (17). The relative risk of 
developing HCC increases by 15–20-fold in patients with 
HBV compared to uninfected patients (18) with an annual 
incidence of HCC in hepatitis B carriers of 0.5% (19,20). It 
is thought that 10–16% of patients with HCC in the US are 
infected with HBV (21). 
HBV is unique in that patients with the disease are at 
increased risk of developing HCC, even in the absence 
of cirrhosis. This is in contrast to chronic hepatitis C and 
other causes of liver disease where cirrhosis is a prerequisite 
to the development of HCC. The pathogenesis of HBV is 
distinctive because HBV initiates hepatic carcinogenesis 
by gaining entry into hepatocytes leading to integration 
into the host genome with subsequent alteration of the 
host DNA/RNA (22). This can cause structural alterations, 
sequence variations, deletions and inhibition of tumor 
suppressor genes leading to the development of cancer 
(23-26). Of note, Liu et al. showed risk factors for 
development of HCC in the setting of HBV in the absence 
of cirrhosis was associated with male gender and higher 
viral loads (27). HBV genotype also appears to play a role 
as studies have shown that genotype C and F CHB patients 
are more likely to develop HCC when compared to other 
genotypes (28,29). In addition, the basal core promoter 
T1762/A1764 mutation has been directly linked to the 
development of HCC (27).
Due to this increased risk of developing HCC, certain 
patient populations infected with HBV should undergo 
surveillance for HCC. Screening options include regular 
blood work including liver function tests, alpha-fetoprotein 
(AFP) and abdominal ultrasound every 6 months. Patients 
at increased risk include Asian men >40, Asian women >50 
and all patients with cirrhosis regardless of age (30). In 
addition, patients should receive extra consideration for 
screening if they meet any of the following criteria: patients 
with a first degree relative with HCC, African patients, 
patients co-infected with HIV or HCV and patients with 
evidence of active disease (30). Stratifying those patients 
with CHB at highest risk for HCC is still unclear and has 
led to multiple scoring models designed to assess this risk. 
These include the individual prediction model (IPM), CU-
HCC score, GAG-HCC score, NGM1-HCC, NGM2-
HCC, REACH-B score and the PAGE-B score (31). While 
the initial models were not fully validated, more recently 
developed models have shown more promise and multiple 
have now been validated and are currently in use (31).  
The CAMD scoring system was created by Hsu 
et al. to assess the risk of development of HCC in 
patients with HBV undergoing treatment with antiviral 
therapy (32). This score was created using a Taiwanese 
cohort and validated by a Hong Kong cohort, the scoring 
system uses readily available information (cirrhosis, age, 
male sex and presence of type 2 diabetes mellitus) to stratify 
patients into low, intermediate and high-risk groups (32). 
Based on the results of this study, the authors concluded 
that the low and high-risk groups had distinctly different 
risks of developing HCC (32). The risk of HCC was so 
small in the low-risk group, annual incidence of 0.3%, that 
the need to adhere to current screening guidelines was 
questioned but no formal recommendations were made (32).
The risk estimation for hepatocellular carcinoma in 
chronic hepatitis B (REACH-B) score is another validated 
scoring system used to predict risk of HCC in patients with 
CHB without cirrhosis (33,34) Developed using a Chinese 
cohort and validated in separate cohorts from Hong Kong 
and South Korea, this score used age, sex, HBeAg status, 
HBV DNA and alanine aminotransferase levels in patients 
without cirrhosis to assess the risk of developing HCC 
(33,34). Ultimately, the 17-point risk score was able to 
reliably predict the likelihood of developing HCC at 3, 5 
and 10 years (33,34). A revised version of REACH-B, which 
incorporated HBsAg levels, has also been developed to 
provide further clarification of high-risk groups (35). 
While previous scoring systems focused mainly on 
Asian population, the PAGE-B score was developed in 
attempt to risk-stratify Caucasian patients with CHB being 
treated with antiviral therapy (36). This scoring system 
incorporates only three factors (age, gender and platelets) 
and was developed using a derivation and validation group 
in patients taking modern antiviral therapies (entecavir and 
tenofovir) (36). A modified PAGE-B score has subsequently 
been created to identify CHB at risk of developing HCC in 
Asian populations (37). Overall, being able to predict which 
patients with CHB are most likely to develop HCC allows 
providers to focus surveillance on the groups at highest risk. 
Although treating CHB does not completely eliminate 
the risk of getting HCC, it does significantly lower the 
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chance of developing it. A study published by Nguyen et al 
found that treatment with tenofovir in patients with CHB, 
with or without cirrhosis, decreased the risk of developing 
HCC from 20.13% for the untreated group compared to 
4.69% in the treated group over an 8-year period (38).
There are multiple treatment options for patients 
with HBV who do develop HCC. These include ablation 
(radiofrequency ablation or the injection of ethanol), 
embolization (chemoembolization vs radioembolization), 
radiation, resection and liver transplantation (30,39). 
It has recently been demonstrated that patients treated 
for HBV prior to partial liver resection have better 
outcomes including lower incidence of microvascular 
invasion and reduced risk of early cancer recurrence (40). 
Immunotherapy and chemotherapy are the last line of 
treatment as palliative measures for metastatic disease (30). 
The specific type of treatment will depend on the size of 
the tumor, whether there are one or multiple tumors, local 
experience with the different modalities and the presence/
absence of widespread disease. 
Criteria for treatment
Patients with CHB have higher rates of many liver-related 
complications including cirrhosis and HCC. Due to the 
stability of cccDNA, the eradication and cure of hepatitis B 
is extremely difficult. This difficulty has led to a paradigm 
shift in chronic hepatitis B treatment, from the goal of 
eliminating the virus to suppressing viral replication. When 
considering viral suppression, not all patient populations 
have a shown long-term benefit, such as decreased liver-
related complications of CHB (10). Because of this careful 
selection when considering treatment is important (10). 
Thus, the decision to treat patients with CHB is critical as 
treatment will ultimately lead to significant improvement of 
health outcomes in those populations who meet criteria. 
The three main criteria used to determine if a patient 
should be treated for CHB are serum HBV DNA levels, 
serum ALT levels and the severity of liver disease (10,12,13). 
Other factors that should be considered are age, overall 
health status, family history of HCC or cirrhosis and 
extrahepatic manifestations of disease (10,12,13).  
Currently, differentiating between immune-active and 
immune-tolerant states of chronic hepatitis B has important 
treatment implications, though this may change in the 
future (Table 1) (10). Immune-active CHB is defined as 
ALT levels ≥2 the upper limit of normal (ULN), defined as 
>35 U/L for men and >25 U/L for women, or significant 
histological evidence of disease plus elevated HBV DNA 
(above 2,000 IU/mL for HBeAg negative or above 
20,000 IU/mL for HBeAG positive patients) (10). It is 
worth noting that the indication for treatment is mostly 
independent of HBeAg status (10,12,13).
Antiviral therapy is currently recommended for immune-
active CHB to reduce the risk of liver related complications 
of the disease (10). Additionally, all  patients with 
decompensated or compensated cirrhosis who are HBsAg-
positive should be treated regardless of HBV DNA level, 
ALT level or HBeAG status (10). In contrast, treatment is 
not recommended for patients with immune-tolerant CHB 
as the risk of developing complications is thought to be 
much lower in this population (10).
Other patients with CHB to consider treating include 
HBsAg-positive pregnant women but only if the HBV-
DNA level is >200,000 IU/mL (10).  Treatment is 
recommended to decrease the risk of perinatal transmission, 
especially because the risk of CHB is very high for infants 
despite vaccination and hepatitis B immunoglobulin 
(HBIG) (10). Patients with chronic HBV who plan to start 
immunosuppression therapy for any reason should also be 
treated to prevent a reactivation flare. 
Prior studies have shown that patients with CHB who 
have significantly elevated HBV DNA (>20,000 IU/mL) 
are at increased risk for developing HCC and cirrhosis 
regardless of ALT levels (15,41). Despite this, current 
guidelines do not recommend treatment of immune-
tolerant patients with high HBV DNA levels (10,13). A 
new study by Kim et al. demonstrated that this population 
may actually benefit from receiving early treatment (42). In 
this study, the authors found that immune-tolerant patients 
who were not treated for CHB had a higher risk for HCC, 
death and need for liver transplant compared to patients with 
immune-active disease treated with antiviral therapy (42). 
Moreover, in patients with mildly active disease (ALT 
levels 1–2× the ULN), the risk of HCC, death and need for 
liver transplant were increased even further (42). Based on 
these results, the authors surmised that many occurrences 
of HCC, transplantation and death could be avoided by 
treatment of CHB during the immune-tolerant phase (42). 
While current guidelines continue have not yet changed 
based on this data, with more research on the topic the 
guidelines may change in the future.
Adherence to treatment is as important as careful 
selection of patients who meet criteria for treatment. A 
recent 10-year longitudinal observational study by Shin et al 
demonstrated this by showing that patients who were non-
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adherent to treatment had an increased risk of complications 
from cirrhosis, HCC, and mortality when compared 
with patients with adherence rates of 90% or higher (43). 
Specifically, patients with adherence rates <90% had a 
2.9 times higher rate of both cirrhotic complications and 
HCC (43). These patients also had a significant increase in 
liver-related (14.3-fold) and all-cause mortality (5-fold) (43). 
Not surprisingly, patients with good adherence rate also had 
a higher rate of virologic response, maintained virologic 
response and had lower rates of virologic breakthrough (43). 
Of note, patients who receive long-term treatment for 
CHB have similar overall and liver-related survival rates to 
those in the general population (except those with HCC) 
over an 8-year follow up period (44). Patients who received 
treatment also had improvement in histological findings 
of fibrosis and reversal of early liver decompensation (36). 
These findings again support the need for treating patients 
with CHB. 
Despite the mounting evidence of improved outcomes of 
patients with CHB who receive treatment, global treatment 
rates remain low (45). In 2016, only one in six patients 
diagnosed with HBV worldwide received treatment (45). 
This is somewhat surprising given the international market 
price of the two most common HBV medications (tenofovir 
and entecavir) has decreased significantly in recent years (45). 
For example, the price of generic tenofovir declined 85% 
from 2004 to 2016 (45). 
Overall, treatment of patients with CHB is critical to 
help control this disease. Knowing who to treat is a vital 
aspect. Also, those who are treated should be monitored 
closely for adherence. These habits will lead to better 
outcomes and longer lives for patients living with this 
disease.   
Treatment options
The treatment for CHB has evolved dramatically over 
the last 3 decades. The first known therapy for CHB was 
interferon-α (IFN-α) that was introduced in the early 
1990s (46). Interestingly, it is the only known medication 
that can actively degrade cccDNA but the response rates 
to treatment are low with less than 10% ever testing 
negative for HBsAg and less than 50% demonstrating viral 
suppression (10). Furthermore, the severity of adverse 
side effects associated with IFN precluded the use of this 
therapy for all populations (47). The paradigm shifts away 
from complete elimination of the virus to suppression led to 
the introduction of nucleos(t)ide analog inhibitors (NAIs). 
The introduction of Lamivudine (LAM) in 1998 
presented an oral regimen that was highly effective at 
suppressing viral load, which subsequently decreased liver-
related morbidity and mortality (48). Unfortunately, data 
indicated that HBV would quickly develop resistance to 
LAM after as little as 1 year of therapy (49). Indeed, in a 
5-year study, the incidence of LAM resistance increased 
from 23% at 1 year to 65% in 5 years (49). Moreover, 
longer duration of therapy led to increased risk of resistance 
development (49). Following the addition of LAM, several 
other therapies have been developed but the current first-
line medications have largely supplanted all other available 
treatment options (10,13). This is primarily due to the high 
genetic barrier for resistance development in HBV (48). 
There are 3 current first-line treatment options: 
entecavir (ETV), tenofovir disoproxil fumarate (TDF), and 
tenofovir alafenamide fumarate (TAF). Since eradication 
of HBV is not universally feasible with current therapies, 
other endpoints are used to monitor efficacy of treatment 
for CHB. These markers include normalization of 
serum ALT, HBeAg seroconversion, and HBV DNA 
suppression (10). 
Entecavir (ETV)
Entecavir is a guanosine analog that leads to chain 
termination when incorporated into HBV DNA during 
replication (48). The effectiveness of ETV has been 
demonstrated in both HBeAg-positive and negative 
patients and has proven to have sustained long-term 
benefits in liver-related morbidity and mortality outcomes 
(50-52). The side effect profile of ETV is mostly 
benign with the most concerning side effect being the 
development of renal disease (53). While ETV does not 
appear to cause renal failure, it may lower the GFR and 
dose adjustment is required depending on degree of renal 
disease (53). Development of resistance to ETV has been 
documented and the risk of HBV resistance to ETV therapy 
was noted to be 1.2% after 5 years of therapy (54). This 
has led to the phrase ‘high-genetic barrier of resistance’ 
when describing ETV, as well as TAF/TDF. However, 
in patients who are LAM-experienced the risk of HBV 
resistance was noted to be 51% after 5 years as ETV is 
a pyrimidine analog similar to LAM (54). Therefore, in 
LAM-inexperienced patients, ETV can be considered 
first-line therapy in patients (10).
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Tenofovir (TAF/TDF) 
Tenofovir is an adenosine analog that, like ETV, leads 
to chain termination during HBV replication (48). 
Tenofovir disoproxil fumarate (TDF) was the first tenofovir 
formulation available and was FDA-approved for use on 
the basis of its efficacy when compared to a previously used 
agent named adefovir (55-57). The effectiveness of TDF 
is comparable to ETV, which is why either is acceptable as 
first-line therapy for CHB (10). Unlike ETV, there are no 
documented cases of resistance to TDF therapy (58). The 
side effect profile for TDF is also relatively benign except a 
small portion of patients who have developed drug-related 
decreased bone density as well as renal toxicity (55,59). 
Dosage adjustment is required in the setting of renal disease 
(55,56). The increased risk of osteopenia and renal toxicity 
led to the development of tenofovir alafenamide (TAF), 
which is noted to have the same efficacy of TDF but has a 
somewhat better safety profile (60). 
Future therapies
Although current therapies for CHB are effective in 
suppressing the virus and causing normalization of ALT, 
there is currently no cure for HBV. Additionally, all first-
line therapies require indefinite or prolonged treatment. 
Several novel therapies are under development that explore 
a variety of different treatment targets.
HBV entry inhibitors
One potential target currently being studied is inhibiting 
the entry of HBV particles into the hepatocyte. The viral 
particle does this through binding of specific proteins with 
the hepatocyte to gain entry (61,62). A compound has 
been developed, myrcludex B, that may inhibit viral entry 
by blocking the hepatocyte proteins required for HBV 
binding (63). A phase 1b/2a study was conducted in 24 
patients co-infected with HBV and hepatitis D virus (HDV) 
which randomized patients to have either Myrcludex B, 
pegylated interferon α (PEG-IFN), or both and found that 
the use of myrcludex B with PEG-IFN was effective for 
viral suppression after 24 weeks (64). While these results 
are promising, the concern is that the drug acts on a bile 
acid transporter and may affect the non-infectious related 
function of the transport (64,65). In addition, this drug may 
require PEG-IFN to be effective however new compounds 
are being developed that may circumvent this issue (64,65).
Nucleocapsid assembly inhibition
The replication of HBV DNA occurs in nucleocapsids 
that are assembled prior to replication (66). Therefore, 
if the assembly of the nucelocapsid can be disrupted, the 
replication of viral DNA can be stopped (66). To that 
end, several compounds have been developed which are 
in preclinical or clinical development that act by either 
forming empty nucleocapsids which lack HBV DNA or 
non-capsid polymers (66). Using cellular models, these 
compounds have shown promising results in terms of 
antiviral activity (67,68).
DNA editing technologies
The advent of DNA-editing technology has funneled 
interest into development of a treatment that can specifically 
inactivate, or even eradicate, cccDNA from hepatocytes 
without damaging the hepatocyte chromosomes (66). The 
use of clustered, regularly interspaced short palindromic 
repeats (CRISPR)/CAS9 can edit the HBV cccDNA in a 
Hepatitis B-infected cell line (69,70). The specifics on how 
this can be translated into infected patients, as an efficient 
delivery system to infected hepatocytes, has not yet been 
developed and is still under investigation (66).
Conclusions
Treating CHB has become the next frontier in the treatment 
of viral hepatitis after the highly effective antiviral cure 
for hepatitis C has become readily available. CHB afflicts 
millions worldwide and understanding the pathophysiology 
and natural history of the disease has important screening 
and treatment implications for the disease. Current 
therapies are effective in suppressing the viral replication 
and improving liver-related outcomes but no virological 
cure has yet become available. New and exciting research in 
the field holds promise in preventing viral replications and 
hopefully can lead to a cure for this disease.
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